OXB

Oxford Biomedica expands strategic partnership with Bristol Myers Squibb

Oxford Biomedica has signed a new Commercial Supply Agreement with Bristol Myers Squibb for the manufacture and supply of lentiviral vectors for CAR-T programmes...

February 4, 2026

Oxford BioMedica plc -3.8% potential downside indicated by Deutsche

November 15, 2024

Oxford BioMedica plc -5.9% potential downside indicated by Deutsche

November 4, 2024

Oxford BioMedica plc -5.0% potential downside indicated by Deutsche

October 21, 2024

Oxford BioMedica plc -9.9% potential downside indicated by Numis

April 5, 2024

Oxford BioMedica plc -4.6% potential downside indicated by Numis

March 22, 2024

Oxford BioMedica plc 3.3% potential upside indicated by Liberum Capital

October 10, 2023

Oxford BioMedica plc 3.7% potential upside indicated by Liberum Capital

September 29, 2023

Oxford Biomedica enters into agreement with Homology and proposes to raise proceeds of approx. £80 million

January 28, 2022

Oxford Biomedica total revenues increased by 37% to £87.7 million

April 15, 2021

Oxford BioMedica Eying up long-term value

July 8, 2019

Oxford BioMedica De-leveraging the balance sheet

June 24, 2019

Partnering strategy delivering profitability

September 20, 2018

Oxford BioMedica Risk-sharing in cystic fibrosis gene-therapy

August 17, 2018

Oxford BioMedica Gene-therapy for Parkinson’s: clinical progression

June 18, 2018

Oxford BioMedica plc New era for cell and gene therapies

September 14, 2017

Oxford BioMedica Delivering commercial gene-therapy vector

March 31, 2017

News and Interview Alerts

Company Presentations

Cerillion Plc Annual KPIs. Substantial Pipeline. Stronger Competitive Position

RECI presentation: High-yielding, controlled-risk lending supports near 10% dividend yield

Q&As

ACG Metals positioned for strong cash generation and long-term value as copper production ramps up, highlights DIVI fund manager

6 February 2026

BlueNord ASA fund manager expects very substantial cash generation for years

6 February 2026

Primary Health Properties surplus cash fuels generous dividend, Gervais Williams impressed

4 February 2026

Arbuthnot Banking Group ‘remarkably low valuation given its prospects’ says DIVI Fund Manager

4 February 2026

Hardman & Co

NB Private Equity Partners 2025 CMD: good returns from low-risk PE model

10 December 2025

Real Estate Credit Investments (RECI): Investor Day: opportunities aplenty

2 December 2025

Volta Finance: Liquid access to outperforming private credit

6 October 2025

Real Estate Credit Investments: What RECI brings to investors

15 September 2025

Chesnara Plc: Showing good operational progress

8 September 2025

Green News

Ilika Plc: Solid-State Breakthroughs Put Stereax and Goliath in the Spotlight (Video)

23 January 2026

Drax expands FlexGen platform with Flexitricity acquisition

21 January 2026

View all Sustainable sectors, Plcs and news >>

Search

Latest Interviews

The Diverse Income Trust: Why Gervais Williams Is Doubling Down on Overlooked UK Small Caps (video)

Ilika Plc: Solid-State Breakthroughs Put Stereax and Goliath in the Spotlight (Video)

BrokerTalk

Sintana Energy Strengthens Position with ExxonMobil Settlement, Eyes Growth in 2026 – Auctus Advisors LLP

4 February 2026

Naked Wines Broker Tips Over 120% Price Upside on Profitable Growth – Panmure Liberum

2 February 2026

Alkemy Capital Gains Momentum with Major 5 Year Glencore Deal and Project Financing – Zeus

28 January 2026

Funds

ACG Metals positioned for strong cash generation and long-term value as copper production ramps up, highlights DIVI fund manager

6 February 2026

BlueNord ASA fund manager expects very substantial cash generation for years

6 February 2026

Primary Health Properties surplus cash fuels generous dividend, Gervais Williams impressed

4 February 2026

Arbuthnot Banking Group ‘remarkably low valuation given its prospects’ says DIVI Fund Manager

4 February 2026

View all Funds, Market Insights and news >>

FTSE 100 News

UK Broker Ratings

Workspace Group PLC (WKP.L) Investor Outlook: What the 14.29% Potential Upside Means for You

6 February 2026

Zigup Plc (ZIG.L) Stock Analysis: Industrial Rental Services Giant with a 30% Upside Potential

6 February 2026

WH Smith PLC (SMWH.L) Investor Outlook: Navigating Potential Upside Amidst Market Challenges

6 February 2026

XPS Pensions Group PLC (XPS.L): Analyst Consensus Points to 29% Upside Potential for UK-Based Pension Specialist

6 February 2026

WORLDWIDE HEALTHCARE TRUST PLC (WWH.L) Stock Analysis: A Look at Recent Price Movements Amidst Strong Buy Ratings

6 February 2026

May 10, 2024

Oxford Biomedica expands strategic partnership with Bristol Myers Squibb

Oxford Biomedica has signed a new Commercial Supply Agreement with Bristol Myers Squibb for the manufacture and supply of lentiviral vectors for CAR-T programmes...